Compare FKWL & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | SRZN |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0M | 271.6M |
| IPO Year | 1997 | 2020 |
| Metric | FKWL | SRZN |
|---|---|---|
| Price | $2.37 | $17.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $38.00 |
| AVG Volume (30 Days) | 11.0K | ★ 169.9K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,086,901.00 | $3,477,000.00 |
| Revenue This Year | N/A | $75.35 |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.65 | N/A |
| 52 Week Low | $2.21 | $11.35 |
| 52 Week High | $5.48 | $35.00 |
| Indicator | FKWL | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 25.28 |
| Support Level | $2.21 | $17.44 |
| Resistance Level | $2.40 | $23.90 |
| Average True Range (ATR) | 0.06 | 1.39 |
| MACD | -0.01 | -0.58 |
| Stochastic Oscillator | 20.51 | 8.03 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).